Company: ACBM
Filing Date: 2025-07-18
Form Type: 10-K
Source: 0001640334-25-001245
Chunk: 475

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-18
Form: 10-K
Item: Item 7
Chunk 475
---
 as of December 31, 2023 and 2022, respectively. Future minimum lease payments under operating leases at December 31, 2023 were as follows: 2024 $27,780 2025  27,780 Thereafter  - Total  55,560 Less Imputed interest  (3,327 )Operating lease liabilities $52,233      The Company recognized total lease expense of $26,280 and $26,280 for the years ended December 31, 2023 and 2022, respectively.

 F-14Table of Contents

NOTE 8 – CONCENTRATION Revenue and accounts receivable The Company did not generate any revenue for the year ended December 31, 2023 and did not have any accounts receivable at December 31, 2023. Of the accounts receivable of $638,500 at December 31, 2022, the Company collected $158,500 from customer A and $0 from customer B and wrote off $480,000. The following table sets forth information to customers who accounted for 10% of more of the Company’s revenue for the year ended December 31, 2022 and accounts receivable at December 31, 2022.   Percentage of revenueFor the year ended December 31, 2022  Percentage of Accounts receivableAs ofDecember 31, 2022 Customer A  55%  56%Customer B  45%  44%Total (as a group)  100%  100% Purchases During the year ended December 31, 2023, the Company did not purchase inventory. During the year ended December 31, 2022, all purchases of inventory, totaling $518,000 were made from one supplier.

NOTE 9 - SUBSEQUENT EVENTS The Company has evaluated subsequent events that have occurred after the date of the balance sheet through the date of issuance of these financial statements and determined that no subsequent event requires recognition or disclosure to the financial statements.

 F-15